Objective:

To synthesize SORT1 biology in calcification-related risk states and discuss its roles in vascular and valve tissues, emphasizing its therapeutic implications.

Key Findings:

• Sortilin is linked to cardiovascular calcification through its regulation of lipid and glucose metabolism, impacting clinical outcomes.
• Elevated plasma sortilin levels are associated with hypertension and cardiovascular risk factors, suggesting a potential biomarker role.
• Sortilin contributes to hypertension by disrupting sphingolipid/ceramide homeostasis and inducing oxidative stress, highlighting its therapeutic target potential.

Interpretation:

Sortilin serves as a molecular hub integrating various risk factors for cardiovascular calcification, suggesting its potential as a biomarker and therapeutic target, warranting further research.

Limitations:

• The review does not provide specific pharmacological therapies that can halt or reverse calcification, and further research is needed to fully elucidate sortilin's complex role in dyslipidemia and cardiovascular calcification, particularly in diverse populations.

Conclusion:

Sortilin represents a promising target for understanding and potentially treating cardiovascular calcification, underscoring the urgency of addressing this issue in clinical practice.